Finance

Beta
Lists
4582:TYO
Symbio Pharmaceuticals Ltd
¥72.00
-1.37%
(-1.00) 1D
Jun 4, 2:47:53 PM GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4582...
Open
¥72
High
¥74
Low
¥72
Mkt. cap
5.50B
Avg. vol.
924.62K
Volume
384.20K
52-wk high
¥229
52-wk low
¥71
EPS
-¥103
Shares outstanding
82.40M
No. of employees
91
Open
¥72
High
¥74
Low
¥72
Mkt. cap
5.50B
Avg. vol.
924.62K
Volume
384.20K
52-wk high
¥229
52-wk low
¥71
EPS
-¥103
Shares outstanding
82.40M
No. of employees
91
News stories
From sources across the web
About Symbio Pharmaceuticals Ltd
CEO-
Employees91
FoundedMar 25, 2005
HeadquartersMinato City, Tokyo, Japan
SectorPharmaceutical industry
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
381.98M
324.17M
336.19M
233.46M
Cost of goods sold
91.39M
122.29M
84.64M
60.63M
Cost of revenue
91.39M
122.29M
84.64M
60.63M
Research and development expenses
-819.37M
868.70M
846.40M
1.99B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.09B
518.54M
506.73M
522.11M
Operating expense
1.28B
1.39B
1.35B
2.51B
Total operating expenses
1.37B
1.51B
1.44B
2.57B
Operating income
-984.83M
-1.19B
-1.10B
-2.34B
Other non operating income
10.72M
-1.57M
14.49M
-6.26M
EBT including unusual items
-1.05B
-1.20B
-1.19B
-2.39B
EBT excluding unusual items
-1.05B
-1.20B
-1.09B
-2.39B
Income tax expense
-760.00K
-3.66M
18.88M
13.97M
Effective tax rate
0.07%
0.30%
-1.58%
-0.58%
Other operating expenses
-
-
-
-
Net income
-1.05B
-1.20B
-1.21B
-2.40B
Net profit margin
-274.24%
-369.09%
-360.02%
-1,028.60%
Earnings per share
-
-
-
-
Interest and investment income
-
1.73M
653.00K
2.25M
Interest expense
-50.89M
-29.04M
-11.12M
-16.63M
Net interest expenses
-50.89M
-27.31M
-10.47M
-14.38M
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more